Literature DB >> 33530831

Pathophysiologic mechanisms of cerebral endotheliopathy and stroke due to Sars-CoV-2.

Visesha Kakarla1, Naoki Kaneko2, May Nour2,3, Kasra Khatibi2, Fanny Elahi4, David S Liebeskind3, Jason D Hinman3.   

Abstract

Cerebrovascular events have emerged as a central feature of the clinical syndrome associated with Sars-CoV-2 infection. This increase in infection-related strokes is marked by atypical presentations including stroke in younger patients and a high rate of hemorrhagic transformation after ischemia. A variety of pathogenic mechanisms may underlie this connection. Efforts to identify synergism in the pathophysiology underlying stroke and Sars-CoV-2 infection can inform the understanding of both conditions in novel ways. In this review, the molecular cascades connected to Sars-CoV-2 infection are placed in the context of the cerebral vasculature and in relationship to pathways known to be associated with stroke. Cytokine-mediated promotion of systemic hypercoagulability is suggested while direct Sars-CoV-2 infection of cerebral endothelial cells may also contribute. Endotheliopathy resulting from direct Sars-CoV-2 infection of the cerebral vasculature can modulate ACE2/AT1R/MasR signaling pathways, trigger direct viral activation of the complement cascade, and activate feed-forward cytokine cascades that impact the blood-brain barrier. All of these pathways are already implicated as independent mechanisms driving stroke and cerebrovascular injury irrespective of Sars-CoV-2. Recognizing the overlap of molecular pathways triggered by Sars-CoV-2 infection with those implicated in the pathogenesis of stroke provides an opportunity to identify future therapeutics targeting both Sars-CoV-2 and stroke thereby reducing the impact of the global pandemic.

Entities:  

Keywords:  Sars-CoV-2; endothelia; infection; inflammation; stroke

Mesh:

Substances:

Year:  2021        PMID: 33530831      PMCID: PMC8142132          DOI: 10.1177/0271678X20985666

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.960


  112 in total

Review 1.  Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke.

Authors:  Douglas M Bennion; Emily Haltigan; Robert W Regenhardt; U Muscha Steckelings; Colin Sumners
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

2.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

3.  Furin inhibition prevents hypoxic and TGFβ-mediated blood-brain barrier disruption.

Authors:  Julia Baumann; Sheng-Fu Huang; Max Gassmann; Chih-Chieh Tsao; Omolara O Ogunshola
Journal:  Exp Cell Res       Date:  2019-07-20       Impact factor: 3.905

4.  Stroke Risk, phenotypes, and death in COVID-19: Systematic review and newly reported cases.

Authors:  Sebastian Fridman; Maria Bres Bullrich; Amado Jimenez-Ruiz; Pablo Costantini; Palak Shah; Caroline Just; Daniel Vela-Duarte; Italo Linfante; Athena Sharifi-Razavi; Narges Karimi; Rodrigo Bagur; Derek B Debicki; Teneille E Gofton; David A Steven; Luciano A Sposato
Journal:  Neurology       Date:  2020-09-15       Impact factor: 9.910

5.  Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor.

Authors:  Sven Wassmann; Michaela Stumpf; Kerstin Strehlow; Andreas Schmid; Bernhard Schieffer; Michael Böhm; Georg Nickenig
Journal:  Circ Res       Date:  2003-12-29       Impact factor: 17.367

6.  FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice.

Authors:  Gopala K Yakala; Hector A Cabrera-Fuentes; Gustavo E Crespo-Avilan; Chutima Rattanasopa; Alexandrina Burlacu; Benjamin L George; Kaviya Anand; David Castaño Mayan; Maria Corlianò; Sauri Hernández-Reséndiz; Zihao Wu; Anne M K Schwerk; Amberlyn L J Tan; Laia Trigueros-Motos; Raphael Chèvre; Tricia Chua; Robert Kleemann; Elisa A Liehn; Derek J Hausenloy; Sujoy Ghosh; Roshni R Singaraja
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

7.  A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Stefan Pöhlmann
Journal:  Mol Cell       Date:  2020-05-01       Impact factor: 17.970

8.  Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome.

Authors:  Craig J Smith; Hedley C A Emsley; Carole M Gavin; Rachel F Georgiou; Andy Vail; Elisa M Barberan; Gregory J del Zoppo; John M Hallenbeck; Nancy J Rothwell; Stephen J Hopkins; Pippa J Tyrrell
Journal:  BMC Neurol       Date:  2004-01-15       Impact factor: 2.474

9.  C-C Chemokine Receptor Type 5 (CCR5)-Mediated Docking of Transferred Tregs Protects Against Early Blood-Brain Barrier Disruption After Stroke.

Authors:  Peiying Li; Long Wang; Yuxi Zhou; Yu Gan; Wen Zhu; Yuguo Xia; Xiaoyan Jiang; Simon Watkins; Alberto Vazquez; Angus W Thomson; Jun Chen; Weifeng Yu; Xiaoming Hu
Journal:  J Am Heart Assoc       Date:  2017-08-02       Impact factor: 5.501

10.  The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.

Authors:  Liang Chen; Xiangjie Li; Mingquan Chen; Yi Feng; Chenglong Xiong
Journal:  Cardiovasc Res       Date:  2020-05-01       Impact factor: 10.787

View more
  6 in total

1.  Role of Endothelial Cells and Platelets in COVID-Related Cerebrovascular Events.

Authors:  Nabil J Alkayed; Marilyn J Cipolla
Journal:  Stroke       Date:  2022-06-08       Impact factor: 10.170

2.  The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre.

Authors:  Cécile Delorme; Marion Houot; Charlotte Rosso; Stéphanie Carvalho; Thomas Nedelec; Redwan Maatoug; Victor Pitron; Salimata Gassama; Sara Sambin; Stéphanie Bombois; Bastien Herlin; Gaëlle Ouvrard; Gaëlle Bruneteau; Adèle Hesters; Ana Zenovia Gales; Bruno Millet; Foudil Lamari; Stéphane Lehericy; Vincent Navarro; Benjamin Rohaut; Sophie Demeret; Thierry Maisonobe; Marion Yger; Bertrand Degos; Louise-Laure Mariani; Christophe Bouche; Nathalie Dzierzynski; Bruno Oquendo; Flora Ketz; An-Hung Nguyen; Aurélie Kas; Catherine Lubetzki; Jean-Yves Delattre; Jean-Christophe Corvol
Journal:  Brain Commun       Date:  2021-06-17

3.  Advances in brain barriers and brain fluids research in 2021: great progress in a time of adversity.

Authors:  Richard F Keep; Hazel C Jones; Lester R Drewes
Journal:  Fluids Barriers CNS       Date:  2022-06-09

4.  Persistent olfactory dysfunction after COVID-19 is associated with reduced perfusion in the frontal lobe.

Authors:  Miguel Yus; Jordi A Matias-Guiu; Lidia Gil-Martínez; Natividad Gómez-Ruiz; Carmen Polidura; Manuela Jorquera; Cristina Delgado-Alonso; María Díez-Cirarda; Jorge Matías-Guiu; Juan Arrazola
Journal:  Acta Neurol Scand       Date:  2022-04-25       Impact factor: 3.915

Review 5.  Cerebral microvascular complications associated with SARS-CoV-2 infection: How did it occur and how should it be treated?

Authors:  Neda Omidian; Pantea Mohammadi; Mona Sadeghalvad; Hamid-Reza Mohammadi-Motlagh
Journal:  Biomed Pharmacother       Date:  2022-08-17       Impact factor: 7.419

6.  Ischemic stroke in patients that recover from COVID-19: Comparisons to historical stroke prior to COVID-19 or stroke in patients with active COVID-19 infection.

Authors:  Naveed Akhtar; Fatma Abid; Rajvir Singh; Saadat Kamran; Yahia Imam; Salman Al-Jerdi; Sarah Salamah; Rand Al Attar; Muhammad Yasir; Hammad Shabir; Deborah Morgan; Sujatha Joseph; Muna AlMaslamani; Ashfaq Shuaib
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.